{
  "id": "interstitial-lung-disease",
  "title": "Interstitial lung disease",
  "lang": "en",
  "source_lang": "en",
  "summary": "Interstitial lung disease comprises diverse disorders that injure lung tissue, impair gas exchange, and may cause progressive pulmonary fibrosis.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Interstitial lung diseases",
    "diffuse parenchymal lung disease",
    "diffuse parenchymal lung diseases",
    "ILD"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/interstitial-lung-disease/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/interstitial-lung-disease/",
      "json": "https://aiwiki.page/zh/interstitial-lung-disease.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Interstitial lung disease (ILD) is a collective term for a heterogeneous group of disorders that damage the gas-exchanging regions of the lungs. These disorders commonly involve the interstitium—the supporting tissue between the air sacs and pulmonary capillaries—but may also affect the air spaces, small airways, blood vessels, and pleura. Their principal tissue responses include inflammation, fibrosis, and combinations of the two. Some forms resolve or remain stable, whereas others progressively scar and distort the lungs.\n\nILD may arise from inhaled substances, medications, radiation, or systemic diseases, particularly autoimmune diseases. In other cases, no cause is identified. Idiopathic pulmonary fibrosis is an important example of the latter and differs substantially from many inflammatory forms in its biology, treatment, and expected course. Consequently, “interstitial lung disease” is not a final diagnosis and does not imply a single treatment.\n\nThe major tasks in evaluating ILD are to identify its cause, recognize its clinical and imaging pattern, assess functional impairment, and determine whether it is progressing. Modern classification integrates clinical information, high-resolution computed tomography, and, when necessary, tissue examination. Treatment is directed toward the underlying disorder and dominant disease process, alongside measures addressing impaired oxygenation, exercise limitation, and other consequences of chronic lung disease."
    },
    {
      "heading": "Classification and development of the concept",
      "text": "The term interstitial reflects the prominence of abnormalities in the alveolar walls and their supporting tissue. It is anatomically incomplete, however: many disorders included under ILD have substantial air-space or airway involvement. Diffuse parenchymal lung disease is therefore used as an overlapping term. Neither label denotes every condition capable of producing diffuse lung opacities. Infection, pulmonary edema, and diffuse alveolar hemorrhage may resemble ILD but often belong to different diagnostic categories.\n\nA practical classification distinguishes diseases with an identifiable cause or association from idiopathic disorders. The former include connective tissue disease–associated ILD, occupational lung disease, drug-induced lung injury, and hypersensitivity pneumonitis. Other groups include granulomatous diseases such as sarcoidosis, and uncommon disorders with distinctive features, such as pulmonary Langerhans cell histiocytosis and lymphangioleiomyomatosis. Childhood interstitial lung diseases constitute a partly separate spectrum that includes developmental abnormalities and inherited disorders of surfactant metabolism.\n\nThe idiopathic interstitial pneumonias are classified by integrated clinical, radiological, and pathological features. Major categories include idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, respiratory bronchiolitis–associated ILD, desquamative interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, and idiopathic lymphoid interstitial pneumonia. Idiopathic pleuroparenchymal fibroelastosis is a recognized rare form. In these names, pneumonia often means an inflammatory or injury pattern rather than a bacterial infection.\n\nA crucial distinction separates a disease from a morphological pattern. Usual interstitial pneumonia (UIP), for example, is a pattern recognized on imaging or tissue examination. Idiopathic pulmonary fibrosis is a clinical diagnosis requiring the appropriate setting and exclusion of known causes. UIP can also occur in rheumatoid arthritis–associated ILD, fibrotic hypersensitivity pneumonitis, and exposure-related disease. Likewise, a nonspecific interstitial pneumonia pattern may be idiopathic or associated with a systemic autoimmune disorder.\n\nClassification developed as imaging and lung pathology became more precise. Liebow and Carrington’s 1969 pathological framework helped distinguish several interstitial pneumonia patterns. Joint American Thoracic Society and European Respiratory Society statements in 2002 and 2013 established and updated multidisciplinary classifications of idiopathic interstitial pneumonias. More recent frameworks also recognize behavior across diagnoses, particularly progressive pulmonary fibrosis, without replacing the search for an underlying cause."
    },
    {
      "heading": "Epidemiology and distribution",
      "text": "The epidemiology of ILD is difficult to summarize with a single number. Studies differ in which disorders they include, how cases are confirmed, and whether they examine general populations, specialist clinics, administrative records, or imaging databases. An estimate for idiopathic pulmonary fibrosis cannot be substituted for an estimate of all ILD. Similarly, an increase in recorded diagnoses may reflect population aging, greater access to computed tomography, changing diagnostic criteria, or improved recognition rather than a corresponding increase in disease onset.\n\nAge distribution varies markedly by subtype. Idiopathic pulmonary fibrosis predominantly affects older adults and is uncommon before age 50. Some inherited surfactant disorders present in infancy or childhood, although related genetic abnormalities can also manifest in adults. Sarcoidosis often presents earlier in adult life than idiopathic pulmonary fibrosis. Autoimmune-associated ILD follows the age and sex distributions of its underlying diseases imperfectly: the characteristics associated with lung involvement may differ from those of the systemic disease as a whole.\n\nSex, smoking, and occupation influence the composition of ILD populations. Idiopathic pulmonary fibrosis is diagnosed more often in men, and many affected people have a smoking history. Smoking is closely associated with respiratory bronchiolitis–associated ILD, desquamative interstitial pneumonia, and adult pulmonary Langerhans cell histiocytosis. Occupational patterns depend on employment in mining, construction, stone fabrication, metalworking, agriculture, and other industries. Engineered-stone fabrication has become a prominent setting for severe silicosis because cutting and grinding silica-rich material can generate intense respirable dust exposure.\n\nGeographic differences also reflect local exposures and case ascertainment. Bird keeping, farming practices, indoor dampness, and industrial processes influence the occurrence and recognition of hypersensitivity pneumonitis. Sarcoidosis varies between populations, but genetic susceptibility, environmental factors, and unequal access to diagnosis are difficult to disentangle. Studies from specialist centers may overrepresent advanced fibrosis or diagnostically complex cases and underrepresent mild disease.\n\nAn important related finding is the incidental interstitial lung abnormality on computed tomography performed for another reason, including lung cancer screening. Such abnormalities are not automatically equivalent to clinically established ILD. Their significance depends on extent, symptoms, physiological impairment, fibrotic features, and change over time. Subpleural fibrotic abnormalities have a greater likelihood of progression than many limited, nonfibrotic findings. Distinguishing incidental abnormalities from established disease has become increasingly important as chest imaging is used more widely."
    },
    {
      "heading": "Causes, exposures, and inherited susceptibility",
      "text": "Inhaled agents produce ILD through several mechanisms. Mineral dusts can persist in lung tissue and provoke macrophage activation, inflammation, and scarring. Silica causes silicosis, while asbestos can cause asbestosis, typically after substantial exposure and a long latency. These disorders belong to the pneumoconioses. Pleural plaques support previous asbestos exposure but do not by themselves establish asbestosis. Exposure attribution depends on the material, intensity, duration, latency, imaging pattern, and other possible causes.\n\nHypersensitivity pneumonitis results from an immune-mediated response to inhaled antigens in susceptible individuals. Recognized sources include avian proteins, molds, and contaminated occupational aerosols. The disease may involve bronchioles, alveoli, and interstitial tissue. Contemporary classification distinguishes nonfibrotic from fibrotic hypersensitivity pneumonitis because established fibrosis substantially affects outcome. Identification of a plausible exposure supports diagnosis, but exposure alone is insufficient; many exposed people never develop disease, and a specific antigen remains unidentified in some well-characterized cases.\n\nSystemic autoimmune diseases are another major group of causes. ILD occurs in systemic sclerosis, rheumatoid arthritis, inflammatory myopathies, Sjögren disease, and mixed connective tissue disease, among others. Lung disease may precede the characteristic joint, skin, or muscle manifestations. Antisynthetase syndrome can combine ILD with inflammatory arthritis, muscle disease, Raynaud phenomenon, and distinctive hand changes, although not every feature is present in every patient. Some autoimmune-associated forms are predominantly fibrotic; others can develop rapidly progressive inflammatory lung injury.\n\nMedications and cancer treatments can also injure the pulmonary parenchyma. Established examples include amiodarone, nitrofurantoin, bleomycin, and some targeted anticancer agents. Immune checkpoint inhibitors can cause pneumonitis with several imaging patterns. Thoracic radiation therapy can produce pneumonitis and later fibrosis, often with a distribution related to the irradiated region. Establishing drug causality requires temporal and clinical assessment because infection, cancer progression, and other lung disorders may look similar.\n\nInherited susceptibility is especially relevant when pulmonary fibrosis affects multiple relatives or occurs unusually early. Variants in telomere-maintenance genes, including TERT, TERC, RTEL1, and PARN, can predispose to fibrosis. Some affected families also show bone marrow or liver disease. Variants in surfactant-related genes, including SFTPC and SFTPA1/SFTPA2, provide another route to disease. The common MUC5B promoter variant is strongly associated with susceptibility to idiopathic pulmonary fibrosis but is neither necessary nor sufficient for its development. Familial disease can display different ILD patterns within the same family."
    },
    {
      "heading": "Tissue injury, repair, and loss of lung function",
      "text": "The normal gas-exchange surface is extremely thin. Alveolar epithelial cells, a shared or closely apposed basement membrane, and capillary endothelial cells separate inhaled air from blood. Type I alveolar cells form most of the exposed surface, while type II cells produce surfactant and participate in epithelial repair. The interstitium contains extracellular matrix, fibroblasts, immune cells, and supporting structures. Injury can disturb this system through inflammation, abnormal repair, deposition of scar tissue, or destruction of normal architecture.\n\nThe relative importance of these processes differs between diseases. In several inflammatory ILDs, immune activation is a major driver, and suppressing it can improve lung abnormalities. In idiopathic pulmonary fibrosis, the prevailing biological model emphasizes recurrent epithelial injury and dysregulated repair in a susceptible, aging lung. Fibroblasts and myofibroblasts accumulate and deposit collagen and other matrix proteins. Signaling pathways involving transforming growth factor beta and growth factors that regulate fibroblast activity help sustain this response.\n\nFibrosis also changes the mechanical environment. Stiff extracellular matrix can promote further fibroblast activation, creating a reinforcing interaction between tissue mechanics and cell signaling. Normal alveolar units are progressively replaced or distorted, small airways become pulled open, and cystic spaces may develop. Cellular senescence, mitochondrial dysfunction, altered epithelial differentiation, and impaired telomere maintenance are implicated in fibrotic disease biology. Their relative contributions vary, and no single pathway explains every form of ILD.\n\nThese structural changes reduce lung compliance, meaning that a greater pressure change is required to produce a given change in lung volume. Breathing therefore becomes mechanically more demanding. Gas transfer is impaired by loss of functioning alveolar-capillary surface, altered membrane properties, and uneven matching of ventilation to blood flow. Oxygen levels often fall during exertion before they become persistently low at rest, because exercise shortens capillary transit time and increases the demand for gas exchange.\n\nPulmonary vascular disease can add a further limitation. Destruction of the vascular bed, low-oxygen vasoconstriction, and vascular remodeling may produce pulmonary hypertension. This increases the workload on the right ventricle and can eventually contribute to right-sided heart failure. The relationship between lung volumes and overall severity is therefore imperfect: two people with similar spirometry may differ substantially in gas-transfer impairment, vascular involvement, exercise capacity, and symptoms."
    },
    {
      "heading": "Clinical manifestations and physiological assessment",
      "text": "The most common presenting symptoms are gradually increasing exertional breathlessness and persistent, often dry cough. The onset may be subtle, with reduced walking speed or avoidance of stairs preceding an explicit complaint of dyspnea. Other disorders present over weeks, and a smaller group causes acute respiratory failure over days. Symptoms alone do not distinguish ILD from heart disease, obstructive lung disease, infection, or deconditioning.\n\nFine inspiratory crackles, often most evident at the lung bases, are characteristic of several fibrotic ILDs. They are sometimes described as resembling the separation of hook-and-loop fasteners. Finger clubbing occurs particularly in idiopathic pulmonary fibrosis but is neither universal nor specific. Wheeze or inspiratory squeaks may indicate associated airway involvement. Examination outside the chest can reveal clues to cause, such as inflammatory joint changes, skin thickening, proximal muscle weakness, Raynaud phenomenon, or characteristic rashes.\n\nPulmonary function testing commonly shows restriction, with reduced total lung capacity. Spirometry may show a reduced forced vital capacity (FVC) with a preserved or increased ratio of forced expiratory volume in one second to FVC. A low FVC alone does not prove restriction; measurement of lung volumes distinguishes true restriction from other explanations. Mild or early ILD can have normal spirometry, and combined pulmonary fibrosis and emphysema may preserve lung volumes despite substantial gas-exchange impairment.\n\nThe diffusing capacity of the lung for carbon monoxide (DLCO) is often reduced. This measurement reflects several components of gas transfer and is affected by hemoglobin concentration, pulmonary vascular disease, emphysema, and technical factors as well as interstitial injury. Interpretation therefore requires context. A marked fall in DLCO with relatively preserved volumes may suggest pulmonary vascular involvement, emphysema, or a combination of processes rather than fibrosis alone.\n\nExercise assessment supplies information that resting tests can miss. The six-minute walk test records functional exercise performance and can document exertional oxygen desaturation. Walking distance is influenced by cardiovascular fitness, musculoskeletal disease, motivation, and oxygen delivery as well as lung pathology. Arterial blood gas analysis is useful in selected settings, particularly severe illness or uncertainty about respiratory failure. Carbon dioxide retention is not usually an early feature of uncomplicated ILD.\n\nSerial assessment is more informative than a single result. Changes in symptoms, FVC, DLCO, oxygen requirement, and exercise performance can indicate progression, but each has measurement variability and potential alternative explanations. A fall in function may reflect infection, pulmonary embolism, heart failure, or anemia rather than worsening interstitial disease. Interpretation therefore combines physiological trends with clinical findings and imaging."
    },
    {
      "heading": "Imaging and pathological patterns",
      "text": "High-resolution computed tomography (HRCT) is central to ILD evaluation. Thin-section images depict the distribution and texture of abnormalities far more clearly than a chest radiograph. Inspiratory imaging is the foundation; expiratory images can demonstrate air trapping, and prone images can help distinguish dependent density from genuine posterior lung abnormality. The protocol is tailored to the diagnostic question rather than requiring every acquisition in every case.\n\nKey findings include ground-glass opacity, reticulation, traction bronchiectasis, honeycombing, nodules, consolidation, and air trapping. Ground-glass opacity means increased lung attenuation through which vessels remain visible. It is not synonymous with reversible inflammation: it can represent partial air-space filling, fine interstitial thickening, or microscopic fibrosis. Traction bronchiectasis describes airway dilatation caused by surrounding retractile fibrosis. Honeycombing consists of clustered, usually subpleural cystic air spaces that indicate established architectural destruction.\n\nA typical UIP pattern has predominantly basal and subpleural fibrosis with honeycombing, with or without traction bronchiectasis, and lacks findings strongly suggesting an alternative diagnosis. A probable UIP pattern has a similar distribution and traction bronchiectasis but no definite honeycombing. The diagnostic significance depends on the clinical setting. In an appropriate older adult with no identified cause, a typical HRCT pattern can establish idiopathic pulmonary fibrosis without surgical sampling.\n\nOther patterns shift diagnostic probabilities rather than uniquely naming a disease. Nonspecific interstitial pneumonia often shows relatively symmetric lower-lung ground-glass opacity and fine reticulation, sometimes with relative sparing immediately beneath the pleura. Organizing pneumonia often produces patchy peripheral or peribronchovascular consolidation. Fibrotic hypersensitivity pneumonitis may combine fibrosis with air trapping and regions of differing attenuation; centrilobular nodules can also be informative. Sarcoidosis commonly produces nodules along lymphatic routes and enlargement of hilar or mediastinal lymph nodes.\n\nWhen tissue is available, histopathology examines the distribution, age, and character of injury. UIP is characterized by patchy fibrosis, architectural distortion, and fibroblast foci, often with relatively preserved tissue adjacent to severely affected areas. Nonspecific interstitial pneumonia is more temporally uniform. Organizing pneumonia features plugs of granulation tissue within small airways and adjacent air spaces. Poorly formed granulomas and airway-centered changes may support hypersensitivity pneumonitis, although findings are variable.\n\nRadiological and pathological patterns are not interchangeable, and neither should be interpreted in isolation. Sampling may miss the most informative region, while advanced disease can obscure the original pattern. Integrating images and tissue with exposure history and systemic findings is more reliable than treating a single descriptive label as the complete diagnosis."
    },
    {
      "heading": "Diagnostic evaluation and multidisciplinary integration",
      "text": "Evaluation begins with a detailed medical history addressing symptom timing, occupational tasks, home and leisure exposures, medications, smoking, family history, and systemic symptoms. Exposure assessment often requires more detail than a job title. The specific material handled, dust-generating process, ventilation, respiratory protection, and timing of exposure may determine whether an occupational association is plausible. Domestic exposures can be intermittent or unnoticed until a structured inquiry is undertaken.\n\nLaboratory investigations are selected to investigate causes and alternative explanations. Autoimmune testing may include antinuclear antibodies, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, and disease-specific antibodies guided by clinical findings. Positive results require interpretation: low-level autoantibodies can occur without a defined systemic autoimmune disease. Conversely, the absence of a particular antibody does not exclude all autoimmune-associated ILD. Some patients have autoimmune features without meeting criteria for a named connective tissue disease; the research category “interstitial pneumonia with autoimmune features” was developed for this situation.\n\nBronchoalveolar lavage obtains cells and fluid from the distal airways and air spaces during bronchoscopy. It can help investigate infection, hemorrhage, and selected unusual disorders. A raised lymphocyte proportion may support hypersensitivity pneumonitis in the appropriate context, but no single lavage result establishes or excludes it. Lavage has a different purpose from lung biopsy and generally provides less direct information about the architecture of fibrosis.\n\nTissue sampling is considered when the remaining uncertainty is important enough to justify its risks. Surgical lung biopsy can provide large specimens but entails anesthesia, postoperative complications, and a risk of severe deterioration. Transbronchial lung cryobiopsy obtains larger samples than conventional forceps biopsy and is used in experienced centers for selected patients. It also carries risks, notably bleeding and pneumothorax. Biopsy is not required for every ILD and may add little when clinical and imaging findings already support a confident diagnosis.\n\nMultidisciplinary discussion brings together respiratory physicians, thoracic radiologists, and pulmonary pathologists, with rheumatologists, occupational specialists, or other experts when relevant. Its purpose is to reconcile evidence rather than to make every case fit a rigid category. A diagnosis may be highly confident, provisional, or unclassifiable. Unclassifiable ILD can result from incomplete data, conflicting findings, overlapping processes, or an inability to obtain tissue safely.\n\nThe differential diagnosis includes infection, heart failure, drug toxicity, malignancy, pulmonary vascular disease, and other causes of diffuse lung abnormalities. Diagnostic revision may become necessary when new exposure information, systemic manifestations, or longitudinal behavior emerges. This is particularly relevant when lung disease precedes a recognizable autoimmune condition or when an initially inflammatory process evolves into a predominantly fibrotic one."
    },
    {
      "heading": "Disease-directed treatment and clinical-trial evidence",
      "text": "Treatment varies substantially between ILD subtypes. Removal of an identified harmful exposure is central to exposure-related disease, although established fibrosis may persist or progress after exposure ends. In drug-induced lung injury, identifying and withdrawing the implicated medication is a major component of management. For occupational diseases, preventing further exposure also involves workplace controls and regulatory measures. The biological response and reversibility depend on the agent, cumulative injury, and stage of disease.\n\nInflammatory and autoimmune-associated ILDs may be treated with corticosteroids or other forms of immunosuppression. Agents used in particular settings include mycophenolate mofetil, azathioprine, cyclophosphamide, and rituximab. Their roles are not interchangeable across diagnoses, and treatment studies differ in strength and scope. Organizing pneumonia often improves substantially with corticosteroid treatment, whereas dense established fibrosis is much less reversible. Infection risk and other treatment toxicities are important components of the evidence on these therapies.\n\nIdiopathic pulmonary fibrosis illustrates why ILD cannot be treated as a single inflammatory disorder. The PANTHER-IPF trial reported in 2012 that the combination of prednisone, azathioprine, and N-acetylcysteine increased deaths and hospitalizations compared with placebo in patients with idiopathic pulmonary fibrosis. This finding changed practice and reinforced the distinction between this disease and ILDs for which immune-directed treatment is beneficial.\n\nThe antifibrotic medicines pirfenidone and nintedanib slow the decline in lung function in idiopathic pulmonary fibrosis but do not reverse established scarring. The ASCEND trial of pirfenidone and the INPULSIS trials of nintedanib, published in 2014, demonstrated effects on FVC decline. In INPULSIS, the between-group difference in annual FVC decline was approximately 94–125 milliliters across the two replicate trials. These results describe an average treatment effect, not an assurance that an individual’s disease will stabilize.\n\nEvidence for antifibrotic treatment extends beyond idiopathic pulmonary fibrosis. The 2019 SENSCIS trial showed that nintedanib reduced the annual rate of FVC decline in systemic sclerosis–associated ILD. The 2019 INBUILD trial studied several non-IPF fibrosing ILDs with progression despite management and found an approximately 107-milliliter annual difference in FVC decline between nintedanib and placebo. Gastrointestinal adverse effects, especially diarrhea with nintedanib, and liver-test abnormalities are relevant limitations; pirfenidone commonly causes gastrointestinal effects and photosensitivity.\n\nThese randomized trials primarily established effects on lung-function decline rather than proving that existing fibrosis disappears. Treatment interpretation distinguishes physiological outcomes from symptoms, hospitalization, survival, and health-related quality of life. The most appropriate disease-directed strategy depends on the underlying diagnosis, inflammatory activity, fibrotic burden, progression, and the evidence available for that particular setting."
    },
    {
      "heading": "Supportive care, rehabilitation, and transplantation",
      "text": "Supportive care addresses consequences that disease-directed therapy may not adequately relieve. Supplemental oxygen is used for clinically significant hypoxemia, including resting or exertional hypoxemia in selected circumstances. The evidence supporting particular oxygen strategies in ILD is less extensive than in chronic obstructive pulmonary disease, and improvements in oxygenation do not necessarily translate into longer survival. Portable delivery systems also differ in their ability to meet the high oxygen requirements that can develop during exertion.\n\nPulmonary rehabilitation combines supervised exercise training, education, and approaches to self-management. Trials in ILD show improvements in exercise capacity and quality of life, although benefits may diminish after a program ends and advanced disease can limit achievable gains. Exercise limitation is not solely a consequence of reduced lung capacity: skeletal muscle dysfunction, inactivity, oxygen desaturation, and cardiovascular factors also contribute. Rehabilitation therefore targets functional performance rather than reversal of fibrosis.\n\nComorbid conditions can materially affect symptoms and outcomes. These include emphysema, obstructive sleep apnea, coronary disease, osteoporosis, anxiety, and depression. Gastroesophageal reflux is common in some ILD populations, but treating reflux solely to improve respiratory outcomes in idiopathic pulmonary fibrosis has not shown established benefit. Pulmonary hypertension requires careful classification because treatment effects differ between pulmonary vascular disorders and lung-disease-associated pulmonary hypertension. The 2021 INCREASE trial demonstrated improved exercise capacity with inhaled treprostinil in pulmonary hypertension associated with ILD.\n\nPrevention and recognition of complications are additional components of care. Respiratory infections can cause substantial deterioration, particularly in patients with limited reserve or receiving immunosuppressive therapy. Vaccination, smoking cessation, and attention to medication-related infection risk are therefore incorporated into clinical care. Nutritional problems can include obesity, muscle loss, or weight loss related to advanced disease or medication adverse effects. These factors affect exercise performance and, in some cases, transplant eligibility.\n\nLung transplantation can extend survival and improve function in selected patients with advanced ILD. Selection incorporates disease severity and trajectory, age, other organ dysfunction, malignancy risk, frailty, and psychosocial factors. Transplantation replaces the diseased lungs but introduces lifelong risks related to immunosuppression, infection, rejection, and chronic allograft dysfunction. Telomere-related disorders may have implications beyond the lungs, including bone marrow vulnerability, which can complicate transplant management.\n\nPalliative care addresses breathlessness, cough, fatigue, psychological distress, and the practical consequences of serious illness. It can be provided alongside antifibrotic treatment, immunomodulation, rehabilitation, or transplant evaluation. Its role is not limited to the final days of life. Symptom burden and family needs may be substantial even when lung-function measurements change slowly, making functional status and patient-reported experience important complements to physiological monitoring."
    },
    {
      "heading": "Progression, acute deterioration, and unresolved questions",
      "text": "The natural history of ILD ranges from complete or substantial resolution to long-term stability, gradual decline, or rapidly progressive respiratory failure. Underlying diagnosis is a major determinant, but behavior varies within each category. Fibrosis on imaging does not by itself establish an actively progressive course. Conversely, clinically important deterioration can occur before extensive honeycombing develops. Prognostic assessment therefore combines disease identity, current severity, serial change, complications, and general health.\n\nProgressive pulmonary fibrosis provides a shared framework for non-IPF ILDs that worsen over time. The 2022 international clinical practice guideline defined it, in a patient with radiological pulmonary fibrosis other than idiopathic pulmonary fibrosis, as at least two of three features within the preceding year without another explanation: worsening respiratory symptoms, physiological progression, and radiological progression. Physiological criteria included an absolute decline of at least 5 percentage points in FVC percent predicted or at least 10 percentage points in DLCO percent predicted. This is a behavior-based designation, not a new underlying cause.\n\nAcute exacerbation is a particularly serious form of deterioration, best characterized in idiopathic pulmonary fibrosis. It involves an acute, clinically significant respiratory worsening, usually within less than one month, with new bilateral ground-glass opacity or consolidation on a fibrotic background that is not fully explained by cardiac failure or fluid overload. Events may be associated with an identifiable trigger or occur without one. Other urgent explanations, including infection and pulmonary embolism, remain important to investigate.\n\nEvidence for the treatment of acute exacerbations is limited. Corticosteroids have frequently been used, but high-quality evidence establishing an optimal regimen or clear benefit is lacking. Mechanical ventilation in advanced fibrotic disease is associated with poor outcomes, although its role differs when the cause is reversible or when support serves as a bridge to transplantation. Acute deterioration cannot therefore be interpreted simply as an acceleration of the usual chronic course.\n\nResearch seeks better ways to identify which patients will progress and which biological pathways are most relevant to treatment. Candidate biomarkers include circulating proteins associated with epithelial injury and matrix turnover, genetic features, and quantitative imaging measurements. A marker associated with severe disease is not automatically a useful predictor of future decline or a tool for choosing treatment. Validation requires reproducibility, comparison with existing clinical measures, and evidence that the result has a meaningful role in care.\n\nOther unresolved questions concern early disease detection, optimal combinations and sequencing of immune-directed and antifibrotic therapies, and trial outcomes that reflect how patients feel and function. FVC is reproducible and clinically informative but does not capture every consequence of ILD. Studies increasingly incorporate exercise measures, cough and breathlessness scales, hospitalization, survival, and patient-reported outcomes. Rare subtypes, childhood disease, and populations with limited access to specialist diagnosis remain less well represented in many clinical research programs."
    }
  ],
  "links": [
    "inflammation",
    "fibrosis",
    "autoimmune-disease",
    "edema",
    "epidemiology",
    "silicosis",
    "lung-cancer",
    "systemic-sclerosis",
    "rheumatoid-arthritis",
    "immune-checkpoint-inhibitor",
    "radiation-therapy",
    "telomere",
    "shortness-of-breath",
    "cough",
    "spirometry",
    "x-ray-computed-tomography",
    "histopathology",
    "medical-history",
    "antinuclear-antibody",
    "biopsy",
    "differential-diagnosis",
    "corticosteroid",
    "immunosuppression",
    "randomized-controlled-trial",
    "health-related-quality-of-life",
    "pulmonary-rehabilitation",
    "palliative-care",
    "prognosis",
    "biomarker",
    "patient-reported-outcome"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}